We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In this episode of ETF Spotlight, I speak with Tim Seymour, CIO of Seymour Asset Management and co-host of CNBC's Fast Money, and Christian Magoon, CEO of Amplify ETFs. We discuss cannabis investing and the Amplify Seymour Cannabis ETF (CNBS - Free Report) , which is actively managed by Tim.
Major indexes have rebounded strongly from their March lows as investors have started looking past the grim economic data and the health crisis. Is there a disconnect between the economy and stock market?
2019 was terrible for most pot stocks and the underperformance continued earlier this year, but many of them rebounded in late March. Is the worst over for pot stocks?
Cannabis shops were deemed essential services in many states and remained open during coronavirus related lockdowns. After some panic buying initially, sales have seen steady growth as consumption continues to rise.
Medical marijuana is legal in 33 states and in the District of Columbia, while recreational use is legal in 11 states and in the District of Columbia, but it remains illegal on the federal level. Should we expect any major changes in the regulatory landscape for marijuana?
GW Pharmaceuticals , Canopy Growth Corporation (CGC - Free Report) . Cronos Group (CRON - Free Report) and Innovative Industrial Properties (IIPR - Free Report) are CNBS’s top holdings. IIPR, a cannabis-focused REIT, has done quite well this year. What do investors need to know about these companies?
We also talk about the Amplify Online Retail ETF (IBUY - Free Report) which is one of the top performing ETFs this year. And we may see a permanent shift in consumer behavior toward online shopping even after the health crisis is over.
Make sure to be on the lookout for the next edition of ETF Spotlight! If you have any comments or questions, please email podcast@zacks.com.
(In full disclosure, Neena owns shares of IBUY in the ETF Investor Portfolio.)
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is it Time to Buy Cannabis Stocks & ETFs?
In this episode of ETF Spotlight, I speak with Tim Seymour, CIO of Seymour Asset Management and co-host of CNBC's Fast Money, and Christian Magoon, CEO of Amplify ETFs. We discuss cannabis investing and the Amplify Seymour Cannabis ETF (CNBS - Free Report) , which is actively managed by Tim.
Major indexes have rebounded strongly from their March lows as investors have started looking past the grim economic data and the health crisis. Is there a disconnect between the economy and stock market?
2019 was terrible for most pot stocks and the underperformance continued earlier this year, but many of them rebounded in late March. Is the worst over for pot stocks?
Cannabis shops were deemed essential services in many states and remained open during coronavirus related lockdowns. After some panic buying initially, sales have seen steady growth as consumption continues to rise.
Medical marijuana is legal in 33 states and in the District of Columbia, while recreational use is legal in 11 states and in the District of Columbia, but it remains illegal on the federal level. Should we expect any major changes in the regulatory landscape for marijuana?
GW Pharmaceuticals , Canopy Growth Corporation (CGC - Free Report) . Cronos Group (CRON - Free Report) and Innovative Industrial Properties (IIPR - Free Report) are CNBS’s top holdings. IIPR, a cannabis-focused REIT, has done quite well this year. What do investors need to know about these companies?
We also talk about the Amplify Online Retail ETF (IBUY - Free Report) which is one of the top performing ETFs this year. And we may see a permanent shift in consumer behavior toward online shopping even after the health crisis is over.
Make sure to be on the lookout for the next edition of ETF Spotlight! If you have any comments or questions, please email podcast@zacks.com.
(In full disclosure, Neena owns shares of IBUY in the ETF Investor Portfolio.)
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>